The Evolution of Acquired Resistance to BRAFV600E kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling

Xu, Guangchao; Luo, Yunbo; Wu, Wenshuang; Liu, Xiaowei; Yu, Xin; Yu, Bao; He, Xiujing; Yu, Jian; Li, Yanna; Yang, Jiqiao; Zhang, Rongjie; Yu, Chunhua; Chen, Hongying; Xu, Jie; Hu, Jianping; Jing, Jing; Shi, Hubing

doi:10.1016/j.jid.2021.07.162

Cited by 14 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug resistance to targeted drugs including BRAF ( 32 ), MAPK ( 33 ), and MEK ( 34 ) signaling pathways in different cancer types affects patient treatment outcomes. Immunotherapy has been observed to show strong antitumor activity in advanced non-small-cell lung cancer.…”

Section: Discussionmentioning

confidence: 99%

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

Jiang

Zhou²,

Huang

2021

Front. Immunol.

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) therapy has provided clinical benefits for patients with advanced non-small-cell lung cancer (NSCLC), but the majority still do not respond. Although a few biomarkers of ICB treatment response have been developed, the predictive power of these biomarkers showed substantial variation across datasets. Therefore, predicting response to ICB therapy remains a challenge. Here, we provided a concise combinatorial strategy for predicting ICB therapy response and constructed the ICB treatment signature (ITS) in lung cancer. The prediction performance of ITS has been validated in an independent ICB treatment cohort of NSCLC, where patients with higher ITS score were significantly associated with longer progression-free survival and better response. And ITS score was more powerful than traditional biomarkers, such as TMB and PD-L1, in predicting the ICB treatment response in NSCLC. In addition, ITS scores still had predictive effects in other cancer data sets, showing strong scalability and robustness. Further research showed that a high ITS score represented comprehensive immune activation characteristics including activated immune cell infiltration, increased mutation load, and TCR diversity. In conclusion, our practice suggested that the combination of biomarkers will lead to a better prediction of ICB treatment prognosis, and the ITS score will provide NSCLC patients with better ICB treatment decisions.

show abstract

Section: Discussionmentioning

confidence: 99%

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

Jiang

Zhou²,

Huang

2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Generally speaking, CRC patients with MSI-H, high TMB, and dMMR are considered to have a positive reaction to ICIs treatment. Thus CRC patients can get a considerably brilliant prognosis (65)(66)(67).…”

Section: Icis Treatment For Colorectal Cancermentioning

confidence: 99%

“…Thus, varieties of researches including basic and clinical are done over enhancing CRC efficiency. Researchers made a conclusion that CRC patients with MSI-H, high TMB and dMMR are demonstrated to get a nice response to ICIs treatment and own a considerably brilliant prognosis (65)(66)(67)(75)(76)(77). Following, FDA approved pebrolizumab used for the treatment of refractory, metastatic solid tumors with mismatch repair defects, high microsatellite instability, and applied nivolumab approval for the treatment of colorectal cancer with a mismatch repair defect and high microsatellite instability.…”

Section: Icis Treatment For Colorectal Cancermentioning

confidence: 99%

“…For the brief mechanism of m6A to relieve the resistance of colorectal cancer patients to anti-PD-1/PD-L1 therapy, we summarize the existing research and speculate the following findings. The m6A modification regulated by the m6A regulator includes the “writer” (methyltransferase_METTL3, METL14), “reader” (signal converter_YTHDC1, YTHDC2) and “eraser” (demethylase_FTO, ALKBH5) ( 67 ). Inhibition of “writers” (methyltransferase_Mettl3, Mettl14) can inhibit m6A modification, enhance the response of pMMR-MSI-L colorectal cancer patients to anti-PD-1 treatment, and significantly slow down tumor growth and prolong patient survival; activation the high expression of “readers” (signal converters_YTHDF1 and YTHDF2) may be related to the good prognosis of patients with colorectal cancer, the increase in the number of TIL, and the down-regulation of PD-L1, and may become a novel related to the immune microenvironment of colorectal cancer.…”

Section: Conclusion and Prospectsmentioning

confidence: 99%

See 1 more Smart Citation

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors

Tong

Smith

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Tumor immunotherapy, one of the efficient therapies in cancers, has been called to the scientific community’s increasing attention lately. Among them, immune checkpoint inhibitors, providing entirely new modalities to treat cancer by leveraging the patient’s immune system. They are first-line treatments for varieties of advanced malignancy, such as melanoma, gastrointestinal tumor, esophageal cancer. Although immune checkpoint inhibitors (ICIs) treatment has been successful in different cancers, drug resistance and relapses are common, such as in colorectal cancer. Therefore, it is necessary to improve the efficacy of immune checkpoint therapy for cancer patients who do not respond or lowly response to current treatments. N6-methyladenosine (m6A), as a critical regulator of transcript expression, is the most frequently internal modification of mRNA in the human body. Recently, it has been proposed that m6A epigenetic modification is a potential driver of tumor drug resistance. In this report, we will briefly outline the relevant mechanisms, general treatment status of immune checkpoint inhibitors in colorectal cancer, how m6A epigenetic modifications regulate the response of ICIs in CRC and provide new strategies for overcoming the resistance of ICIs in CRC.

show abstract

“…In approximately 5% of thyroid cancers, overexpression of insulin-like growth factor 2 binds to protein 3 (IGF2BP3) and low expression of IGF1R inhibit the abnormal growth of tumour cells caused by IGF2BP3 [ 129 ]. The acquired resistance to BRAF inhibitors is maintained by IGF1R-driven tumour vascular reconstruction [ 130 ]. Silencing the m6A methyltransferase like 3 (METTL3) can inhibit the migration ability and Wnt activity in TPC-1 cells.…”

Section: Rna Methylation In Tcmentioning

confidence: 99%

Epigenetic modification and BRAF gene mutation in thyroid carcinoma

et al. 2021

View full text Add to dashboard Cite

Thyroid cancer remains the most prevailing endocrine malignancy, and a progressively increasing incidence rate has been observed in recent years, with 95% of thyroid cancer represented by differentiated thyroid carcinomas. The genetics and epigenetics of thyroid cancer are gradually increasing, and gene mutations and methylation changes play an important roles in its occurrence and development. Although the role of RAS and BRAF mutations in thyroid cancer have been partially clarified,but the pathogenesis and molecular mechanisms of thyroid cancer remain to be elucidated. Epigenetic modification refer to genetic modification that does not change the DNA sequence of a gene but causes heritable phenotypic changes in its expression. Epigenetic modification mainly includes four aspects: DNA methylation, chromatin remodelling, noncoding RNA regulation, and histone modification. This article reviews the importance of thyroid cancer epigenetic modification and BRAF gene mutation in the treatment of thyroid cancer.

show abstract

The Evolution of Acquired Resistance to BRAFV600E kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling

Cited by 14 publications

References 41 publications

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors

Epigenetic modification and BRAF gene mutation in thyroid carcinoma

Contact Info

Product

Resources

About